Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
NCT05391750
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Doctors are doing a study to see the best amount of medicine to use and what effects it has for people with t(11;14) multiple myeloma. This is a kind of cancer that has come back after treatment or doesn't respond to treatment. They are using two medicines called venetoclax and tocilizumab. Venetoclax can stop cancer cells from growing by blocking a protein they need to survive. Tocilizumab may help stop the cancer from growing and spreading. It's also used to treat side effects of other treatments. Doctors think that using these two medicines together might be better at fighting the cancer.
Doctors are doing a study to see the best amount of medicine to use and what effects it has for people with t(11;14) multiple myeloma. This is a kind of cancer that has come back after treatment or doesn't respond to treatment. They are using two medicines called venetoclax and tocilizumab. Venetoclax can stop cancer cells from growing by blocking a protein they need to survive. Tocilizumab may help stop the cancer from growing and spreading. It's also used to treat side effects of other treatments. Doctors think that using these two medicines together might be better at fighting the cancer.
Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Tocilizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Tocilizumab is used to treat side effects from immune therapy in patients with myeloma. Giving venetoclax and tocilizumab may kill more cancer cells.
This phase I trial finds out the best dose and side effects of venetoclax and tocilizumab in treating patients with t(11;14) multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Tocilizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Tocilizumab is used to treat side effects from immune therapy in patients with myeloma. Giving venetoclax and tocilizumab may kill more cancer cells.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
